19-403 - A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
Status: closedToEnrollmentRandomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer
Treatment for Breast Cancer
Contact Us
If you have questions about this trial or are interested in participating, please contact this Clinical Trial’s Coordinator by email at clinical.trials@health.southalabama.edu.
Description
The purpose of this study is to assess the effect of tucatinib vs. placebo in combination with capecitabine and trastuzumab on progression-free survival (PFS) per RECIST 1.1 based on independent central review.
Providers Associated With This Trial
Sub Investigators
![Daniel Cameron]()
View ProfileDaniel G. Cameron, M.D.Medical Oncologist and HematologistAssociate Professor of Interdisciplinary Clinical Oncology
This link will open in a new tab or window.